在新诊断子宫内膜癌中实施普遍 upfront 多基因面板检测:从成本到实践考量
该决策分析比较了当前对所有子宫内膜癌(EC)病例普遍进行错配修复(MMR)免疫组化(IHC)的算法与对所有EC病例 upfront 多基因面板检测(MGPT)、MMR IHC保留用于复发场景的新算法。
要点
- upfront MGPT算法较当前MMR IHC算法每例节省259美元。
- MGPT算法额外识别660例(1%)LS和660例(1%)BRCA1/BRCA2 PV患者。
核心结论
- 对新诊断EC患者采用普遍 upfront MGPT在节省成本和改善高外显率癌症综合征诊断方面是实际可行的考量。
- 将胚系基因检测纳入 upfront 场景是改善遗传咨询和检测可及性的机会,并最终是实现公平和改善EC患者及其家庭生活的途径。
研究设计与样本
- 决策分析,比较当前对所有EC病例普遍进行MMR IHC的算法与对所有EC病例 upfront MGPT、MMR IHC保留用于复发场景的新算法。
- 估计使用upfront MGPT增加的LS诊断数量以及BRCA1和BRCA2 PV患者数量。
主要发现
- MGPT算法每例节省259美元。
- 应用于一年内所有新诊断EC时,MGPT算法识别出660例(1%)当前算法会漏诊的额外LS病例。
- 仅通过实施普遍MGPT,额外诊断660例(1%)BRCA1或BRCA2 PV的EC患者。
临床怎么用
- 作者提出对所有新诊断EC患者优先进行upfront MGPT的算法。
- 作者认为将胚系基因检测纳入upfront场景可改善遗传咨询和检测的可及性,并促进公平。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The routine use of upfront universal germline genetic testing among patients with newly diagnosed endometrial cancer (EC) has been proposed to improve diagnosis of Lynch syndrome (LS) and discover pathogenic variants (PVs) in other cancer susceptibility genes. We propose an algorithm prioritizing upfront multi-gene panel testing (MGPT) for newly diagnosed EC patients. METHODS: A decision analysis compared the cost of the current algorithm of universal mismatch repair (MMR) immunohistochemistry (IHC) for all EC cases to a new MGPT algorithm that employs upfront MGPT for all EC cases and reserves MMR IHC for the recurrent setting. The increase in the number of LS diagnoses using upfront MGPT, and the number of patients with PVs in BRCA1 and BRCA2 are also estimated. RESULTS: The MGPT algorithm demonstrated a cost savings of $259 per patient. Assuming 66,950 new cases of EC per year, this would represent $17.1 M of cost savings per year. When applied to all new diagnoses of EC in one year, the MGPT algorithm identified 660 (1%) additional cases of LS that would have been missed with the current algorithm. An additional 660 (1%) EC patients with BRCA1 or BRCA2 PVs would be diagnosed only through implementation of universal MGPT. CONCLUSIONS: The use of universal upfront MGPT is a practical consideration for patients with newly diagnosed EC for cost savings and improved diagnosis of highly penetrant cancer syndromes. Incorporation of germline genetic testing in the upfront setting represents an opportunity to improve access to genetic counseling and testing, and ultimately an avenue to achieve equity and improve the lives of our patients with EC and their families.
引用
- Levine MD, Barrington DA, Hampel H, et al. Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations. Gynecol Oncol. 2022. PMID: 35871048. doi:10.1016/j.ygyno.2022.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。